-transparent.png){kind=logo}
In 36 patients with primary hyperlipoproteinemia of type II B or IV the effect of bezafibrate, a new derivate of clofibrate, has been compared with the effect of clofibrate. In an open cross-over-study the effect of 1.5 g clofibrate p.d. has been compared with that of 450 mg bezafibrate p.d. for several months. The effect of bezafibrate on plasma triglyceride concentration and plasma cholesterol concentration was more pronounced than that of clofibrate. This difference was statistically significantly only in the concentration of plasma triglycerides of type IV patients. It is obvious that the difference between bezafibrate and clofibrate would have been more pronounced if the dose of bezafibrate had been in the optimal range. Serious side-effects caused by bezafibrate could not be observed.
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
December 1978,
Medizinische Klinik,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
January 1976,
Acta medica Scandinavica,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
January 1984,
Przeglad lekarski,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
October 1979,
MMW, Munchener medizinische Wochenschrift,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
October 1972,
JAMA,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
January 1983,
Polskie Archiwum Medycyny Wewnetrznej,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
April 1977,
International journal of clinical pharmacology and biopharmacy,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
April 1985,
Wiadomosci lekarskie (Warsaw, Poland : 1960),
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
January 1984,
Przeglad lekarski,
K Bolzano, and
F Krempler, and
B Schellenberg, and
G Schlierf
September 1976,
Atherosclerosis,
